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Abstract
Background: Schizophrenia is a severe form of mental illness which is associated with significant and long-lasting
health, social and financial burdens.
The aim of this project is to assess the efficiency of the antipsychotics used in Spain in reducing schizophrenia
relapses under the Spanish Health System perspective.
Material and methods: A decision-analytic model was developed to explore the relative cost-effectiveness of five
antipsychotic medications, amisulpride, aripiprazole, olanzapine, paliperidone Extended-Release (ER) and risperidone,
compared to haloperidol, over a 1-year treatment period among people living in Spain with schizophrenia. The
transition probabilities for assessed therapies were obtained from the systemic review and meta-analysis performed
by National Institute for Health and Clinical Excellence (NICE).
Results: Paliperidone ER was the option that yielded more quality-adjusted life years (QALYs) gained per patient
(0.7573). In addition, paliperidone ER was the least costly strategy (€3,062), followed by risperidone (€3,194),
haloperidol (€3,322), olanzapine (€3,893), amisulpride (€4,247) and aripiprazole (€4,712).
In the incremental cost-effectiveness (ICE) analysis of the assessed antipsychotics compared to haloperidol, paliperidone
ER and risperidone were dominant options. ICE ratios for other medications were €23,621/QALY gained, €91,584/QALY
gained and €94,558/QALY gained for olanzapine, amisulpride and aripiprazole, respectively. Deterministic sensitivity
analysis showed that risperidone is always dominant when compared to haloperidol. Paliperidone ER is also dominant
apart from the exception of the scenario with a 20% decrease in the probability of relapses.
Conclusions: Our findings may be of interest to clinicians and others interested in outcomes and cost of mental
health services among patients with schizophrenia.
Paliperidone ER and risperidone were shown to be dominant therapies compared to haloperidol in Spain. It is
worthwhile to highlight that schizophrenia is a highly incapacitating disease and choosing the most appropriate
drug and formulation for a particular patient is crucial.
The availability of more accurate local epidemiological data on schizophrenia would allow a better adaptation of
the model avoiding some of the assumptions taken in our work. Future research could be focused on this.
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Background
Schizophrenia is a severe form of mental illness that
has varying presentations. As a chronic disease, it is
associated with significant and long-lasting health,
social and financial burdens, not only for patients but
for their families, other caregivers [1] and wider society
[2,3].
According to WHO estimates, schizophrenia affects
approximately 24 million people worldwide [4]. The
most recent publications estimate that the median inci-
dence of schizophrenia varies from 15.2 [5] to 20.0 per
100,000 population/year [6], although it is higher in the
15-35 year-old age group (7 per 1,000 population) [7,8].
There are no recent epidemiological data concerning
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schizophrenia in Spain. Spain does not have a national
registry that would make it possible to know the exact
number of individuals with schizophrenia, although
regional studies estimate the prevalence at 0.6-0.8% for
the adult population (17 years of age and older) [9].
Available estimates from 1995 show that incidence of
schizophrenia was 1.9 per 10,000 inhabitants per year
for people between the ages of 15 and 54 years [10].
Conventional antipsychotic medications (chlorproma-
zine and haloperidol) emerged 50 years ago as the first
tools on the management of schizophrenia, in concert
with other important interventions, such as psychosocial
and economic support and rehabilitation efforts. How-
ever, the unrivalled role of conventional antipsychotic
medications has been continuously challenged by the
wide range of adverse effects of these medications. Over
the last 15 years, several new atypical antipsychotic
medications have been introduced, including sertindole,
risperidone, olanzapine, quetiapine, amisulpride, ziprasi-
done, aripiprazole and paliperidone [11]. In general, the
new antipsychotics have shown themselves to be at least
comparable in efficacy to conventional antipsychotics
but with superior tolerability and a more favourable
adverse effect profile, providing less extrapyramidal side
effects than conventional treatment [8].
However, despite the availability of new antipsychotics,
20-30% of patients have an inadequate response to med-
ication with 15-20% relapsing each year [2,12]. Compli-
ance is one of the factors associated with relapse [13];
however, some patients relapse while taking mainte-
nance medication [14].
Relapse has wider implications for the family in gen-
eral, for the provision of medical and social facilities and
from a health economic perspective [15]. In terms of
quality of life, it has been shown to be associated with
lower quality of life than in other stable medical condi-
tions [16]. Onset of the disease in late adolescence or
early adulthood [2] together with difficulties in employ-
ment and the social stigma associated with schizophre-
nia could be considered the main drivers of the changes
in quality of life seen in these patients [16,17].
Additionally, schizophrenia has been shown to place a
substantial economic burden on both the health care
system and society worldwide due to its potentially large
demands on the healthcare system [18]. The full cost of
schizophrenia is high, although this is rarely appreciated
by health care decision makers or other stakeholders [3].
In Spain, drug’s reimbursement is a central national
decision. However, there is a strong territorial decentra-
lization of health jurisdictions in the Autonomous Com-
munities. Therefore, the final drug financing is an
Autonomous Regions’ responsibility covering almost
100% of population [19]. That means that caring of schi-
zophrenia patients is covered by the public system. In
the practice, schizophrenia is diagnosed and followed-up
by a psychiatrist at a hospital level, after the patient is
being referred by a general practitioner. First drug pre-
scription is usually made by the specialist, but it is
required that the patient attends to a primary care level
asking for drug prescription in a funded way. In the glo-
bal economic crisis environment we face, the efficient
use of available healthcare resources is required to maxi-
mise health benefits for people with schizophrenia and,
at the same time, reduce the emotional distress and
financial implications of the condition to society [18].
Use of atypical antipsychotics could increase the total
cost of the disease as a result of their relatively high
price. However, their effectiveness results in reduced
hospital stays, thus potentially decreasing total outlay.
Indeed, these more expensive treatments could be
cheaper for society in the long run [3]. The efficiency,
understood as combined measure of efficacy and cost,
of treatments for schizophrenia is one key parameter in
the decision-making process [20].
Published economic evaluations suggest that atypical
(second-generation) antipsychotics are cost-effective
when compared with conventional (first-generation)
therapy [21]. The aim of this project was to assess the
efficiency of the antipsychotics used in Spain to reduce




A decision-analytic model was developed using TreeAge
software (© 2009 TreeAge Software, Inc. - Decision Ana-
lysis Software) to explore the relative cost-effectiveness
of antipsychotic medications for people with schizophre-
nia in Spain. Figure 1 shows a schematic representation
of the decision tree used.
The model compares oral amisulpride, aripiprazole,
olanzapine, paliperidone Extended-Release (ER) and
generic risperidone with generic oral haloperidol (pri-
mary comparator) in the treatment of patients with schi-
zophrenia. Zotepine was discarded for not being
marketed in our country.
According to the model structure, six hypothetical
cohorts of people with schizophrenia in remission were
initiated on each of the six oral antipsychotic medica-
tions assessed (first-line antipsychotic).
Patient could stop the first line antipsychotic when
relapsing or due to the development of intolerable side
effects and switch to a second line antipsychotic. People
who stopped the first line antipsychotic for any other
reason were assumed to do so abruptly and were moved
to the no treatment group. These people remained with-
out antipsychotic treatment until they experienced a
relapse. People discontinuing treatment due to side
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effects or for other reasons were assumed not to experi-
ence relapse in the remaining time after the first line
antipsychotic discontinuation occurred. All patients
experiencing a relapse stopped any antipsychotic they
had been receiving while in remission and were treated
for the acute episode; after achieving remission, they
either returned to their previous antipsychotic medica-
tion with the goal of promoting recovery (50% of them)
or switched to a second line antipsychotic drug (the
remaining 50%).
The first line antipsychotic described in the model
structure was one of the six (amisulpride, aripiprazole,
Figure 1 Schematic decision tree model for antipsychotic drugs in patients with schizophrenia.
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olanzapine, paliperidone ER or risperidone) oral antipsy-
chotics evaluated in the analysis. The second line anti-
psychotic following the first line was haloperidol; the
second line antipsychotic following haloperidol was
olanzapine.
The model assessed the relative cost-effectiveness
between the first line antipsychotics only. The purpose
of incorporating medication switching in the model
structure was to check the impact of the lack of effec-
tiveness in relapse prevention (expressed by relapse
rates), intolerance (expressed by discontinuation rates
due to side effects) and unacceptability (expressed by
discontinuation rates due to other reasons) of the first
line antipsychotics on cost and health outcomes and to
present a more realistic sequence of events related to
treatment of people with schizophrenia with antipsycho-
tic medication.
The model assumes that four types of side effects
could be experienced by patients: extra-pyramidal symp-
toms (EPS) [22], clinically significant weight gain
(increase in weight of at least 7% from baseline) and
glucose intolerance or diabetes as a representative fea-
ture of the metabolic syndrome. It must be noted that
acute EPS did not include cases of tardive dyskinesia
[9,23].
Model probabilities
Probabilities for each one of the assessed therapies were
obtained from the systemic review and meta-analysis
performed by NICE [18]. This systematic review was
developed based on the results of 17 randomized clinical
trials (RCT) including 3,535 subjects. All the analyzed
RCTs provided information concerning the three main
parameters considered in the economic model: relapse,
treatment discontinuation due to side effects and treat-
ment discontinuation for other reasons.
Table 1 details the probabilities used in the model.
The probabilities that treatments are best in reducing
relapse over 52 weeks were re-calculated from the prob-
abilities used in the NICE model, with the exception of
zotepine.
Time horizon, perspective and discount rate
The model was run from a third party payer perspective
(National Health System) during a one-year timeframe.
This period was chosen because clinical data on relapse
on discontinuation were taken from trial lasting between
26 and 104 weeks. No robust evidence exists to confirm
that extrapolation of effectiveness data reflects the long-
term effectiveness of antipsychotic medication and its
impact on the course of schizophrenia in real life.
The time horizon is less than one year thus no annual
discount rate was applied [24].
Cost-effectiveness analysis
For each treatment, the average benefit in terms of
Quality adjusted life year (QALY) gained and the aver-
age cost was calculated. The average cost-effectiveness
ratio of each treatment was obtained.
Efficiency was established from the Incremental Cost-
Effectiveness Ratio (ICER), defined as extra cost per
QALY gained [25] with any of the antipsychotics versus
haloperidol:
ICER =
(Cost strategy1)− (Cost haloperidol)
(Effectiveness strategy1)− (Effectiveness haloperidol)
(Efficacy docetaxel)− (Efficacy Pac-1w)
A strategy is considered as cost-effective versus halo-
peridol when ICERs are below the cost-utility threshold
acceptable in Spain (€30,000/QALY gained) [26,27]
A strategy is dominant in comparison to haloperidol,
when effectiveness (in QALYs) is higher, and cost is
lower than the compared drug. In the same way, a strat-
egy is dominated when effectiveness is lower, and cost is
higher.
Utilities
To express outcomes in QALYs, the health states of the
economic model needed to be linked to appropriate uti-
lity scores. Utility scores represent the HRQoL asso-
ciated with specific health states on a scale from 0
(death) to 1 (perfect health); they are estimated using
preference-based measures that capture people’s prefer-
ences on, and perceptions of, HRQoL in the health
states under consideration [18].
Utility scores for remission and relapse were derived
from those published by Lenert et al [28]. Utilities for
acute EPS and weight gain were calculated by multiply-
ing the remission utility value by the expected decre-
ment in utility reported by NICE (0.888 for acute EPS
and 0.959 for weight gain) [18], which was estimated
from the number of people endorsing the presence of
each side effect, as reported in a paper by Lenert and
colleagues [28].
Utilities owing to diabetes mellitus were taken from a
national study carried out in Spain based on EQ-5D tar-
iffs [29]. Utilities arising from complications from dia-
betes were also extracted from the literature [30]. Utility
scores used in the model are detailed in Table 2.
Cost estimation
Costs considered in the model consisted of drug acquisi-
tion costs, inpatient stays due to relapse, outpatient pri-
mary and community care costs of treating adverse events
and metabolic complications of antipsychotic treatment.
Patients under no treatment (following treatment dis-
continuation for reasons other than relapse or presence
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Amisulpride 0.2988 0.0554 0.2435 0.084 0.3163 0.3175 0.2381 0.0317 0.0023 0.0042 0.0130 0.0039 0.0040 0.0157
Aripiprazole 0.2742 0.1582 0.3520 0.119 0.2258 0.1516 0.1167 0.0156
Haloperidol 0.3317 0.0922 0.2516 0.035 0.5367 0.2000 0.1500 0.0200
Olanzapine 0.1996 0.0783 0.2730 0.152 0.2336 0.4172 0.3129 0.0417
Paliperidone
ER
0.1625 0.3287 0.3848 0.525 0.2569 0.2123 0.1592 0.0212
Risperidone 0.2761 0.0994 0.1761 0.086 0.3546 0.2141 0.1606 0.0214
EPS: Extra-Pyramidal Symptoms)
ER: Extended-Release





















of intolerable side effects) were assumed to incur no
costs until they experienced a relapse. Costs associated
with baseline measurements and laboratory tests for
monitoring purposes were omitted from the analysis, as
they were estimated to be the same for all antipsychotic
medications evaluated.
Drug acquisition costs were based on mean doses used
as described by IMS (ICD codes F20) in Spain for each
treatment (Table 3). Prices expressed in public prices
(VAT included) per mg (price weighted by relative sales
by put up) were obtained from the Pharmacist Official
Council Catalogue [31].
The average cost of hospitalisation, including inpatient
stay and pharmacological treatment for people experien-
cing acute episodes, was estimated from hospitalisation
costs for people with schizophrenia, schizotypal and
delusional disorders in Spain, from the disease-related
group 430 (DRG-430, psychosis) [32]
Acute EPS management cost was the equivalent to
one visit to the psychiatrist plus medication adminis-
tered for the event (biperidene 2 mg/8 h during three
months) [33]
Weight gain management cost was equivalent to one
visit to a general physician every three months; this defi-
nition was based on expert opinion.
The cost of diabetes [34,35] and its complications
(amputation [36], fatal myocardial infarction [37], heart
failure [38], ischaemic heart disease [39], non-fatal myo-
cardial infarction [37] and nonfatal stroke [40]) were
obtained from literature.
Unitary costs
All costs were uplifted to 2009 prices, using appropriate
price inflation rates [41]. The unitary costs detailed in
Table 4 were obtained from the literature and from a
Spanish database on health costs [42].
Sensitivity analysis
One-way deterministic analyses were carried out to test
the model’s robustness.
One-way deterministic analysis included modifications
of the following inputs: relapse probabilities and treat-
ment discontinuation probabilities (for adverse events or
for other reasons) that were varied by ± 20%.
Table 3 Acquisition costs of antipsychotic medications (€, 2009)
Strategy Mean Daily Dose used (mg) Price/mg (included VAT in €) Daily Treatment Cost (€) Annual cost (€)
Amisulpride 611.12 0.0086 5.2556 1,918.31
Aripiprazole 15.42 0.4215 6.4995 2,372.33
Haloperidol 8.70 0.0356 0.3097 113.05
Olanzapine 14.65 0.4382 6.4196 2,343.16
Paliperidone ER 6.40 0.8906 5.6998 2,080.44
Risperidone 5.39 0.5566 3.0001 1,095.03
ER: Extended-Release
Table 2 Utility scores





0.7095 Calculated by multiplying remission utility by expected decrement in utilities estimated in the NICE
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Heart failure -0,108
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Results
Deterministic analysis
Total cost per patient and effectiveness measured in
QALYs for the six antipsychotic drugs assessed are
shown in Figure 2. Paliperidone ER was the option that
yielded more QALYs per patient (0.7573), followed by
olanzapine (0.7475), aripiprazole (0.7379), risperidone
(0.7337), amisulpride (0.7333) and haloperidol (0.7232).
In addition, paliperidone ER was the least costly strategy
(€3,062), followed by risperidone (€3,194), haloperidol
(€3,322), olanzapine (€3,893), amisulpride (€4,247) and
aripiprazole (€4,712), in increasing order.
Average cost-effectiveness ratios of these antipsychotic
medications are included in Table 5. Paliperidone ER had
the lowest average cost-effectiveness ratio (€4,043 per
QALY) and aripiprazole the highest (€6,386 per QALY)
Incremental Cost-Effectiveness Ratio
Figure 3 graphically represents the incremental cost-
effectiveness of assessed antipsychotics versus the pri-
mary comparator (haloperidol). Table 5 show ICERs of
assessed antipsychotics versus haloperidol.
Paliperidone ER and risperidone yielded more QALYs
and less cost than haloperidol Thus, they were consid-
ered dominant strategies, while haloperidol was a domi-
nated strategy.
Considering the common threshold accepted in Spain
(€30,000 per QALY gained) [27], olanzapine could also
be considered a cost-effective option compared to
haloperidol.
Both amisulpride and aripiprazole were above the
threshold when compared with haloperidol.
Sensitivity analysis
Table 6 show details of the deterministic analysis per-
formed. Risperidone is always a dominant strategy ver-
sus haloperidol. Paliperidone ER is also a dominant
strategy over haloperidol apart from the scenario where
basecase probability of relapse is reduced by 20%, which
yielded an ICER of €1,687 per QALY gained.
Discussion
To our knowledge, this analysis is the first economic
evaluation assessing antipsychotics for prevention and
treatment of schizophrenia relapses in Spain.
Atypical antipsychotics are cost-effective when com-
pared with first generation antipsychotics (haloperidol),
thus the expected higher acquisition cost of new anti-
psychotics are generally offset by reductions in other
mental healthcare costs, particularly inpatient hospitali-
sation costs. This indicates that second-generation drugs
may be a more efficient choice than traditional antipsy-
chotics [21,43].
Table 4 Unitary cost (€, 2009)
Status Cost (€)
Relapse (hospital cost) 5,589 (1) [32]
Acute EPS (extra-pyramidal symptoms) 85 (2)
Psychiatric medical visit 68 [42]
Biperidene (2 mg/8 h/day) 17 [31]
Weight gain 117 (3)
General physician medical visit 39 [42]
Diabetes Mellitus (control) 855 [34,35]
Amputation 5,857 [36]
Fatal myocardial infarction 1,531 [37]
Heart failure 4,189 [38]
Ischaemic heart disease 2,474 [39]
Non-fatal myocardial infarction 21,610 [37]
Non-fatal Stroke 5,199 [40]
(1) = including inpatient stay and pharmacological treatment
(2) = including medication (biperidene 2 mg/8 hours/day for three months)
plus one medical visit to a psychiatrist































Figure 2 Cost-effectiveness of antipsychotics for relapse prevention. Data shown in the figure for each strategy refer to effectiveness in
QALYs (upper value) and annual cost (€) (lower value).
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Our study showed lower average cost-effective ratios
for paliperidone ER, risperidone and haloperidol than
for olanzapine, amisulpride or aripiprazole.
In the base case of the present analysis, one year of
treatment with paliperidone ER or risperidone compared
with haloperidol were dominant strategies. Our results
are in line with economic evaluations carried out by
other investigators. Risperidone against haloperidol was
also a dominant strategy in Canada [44] and had a
lower risk of relapse [45]. Treatment with olanzapine
resulted in higher costs than risperidone [46], but it was
also cost-effective when compared with haloperidol in a
Mexican study [47]. In the UK, despite equivalence with
respect to the costs of three alternatives, both risperi-
done and olanzapine were cost-effective when compared
with haloperidol due to efficacy gains [48].
Given that the willingness to pay for an additional
QALY in Spain is generally estimated to be within the
range of €30,000 to €45,000 [25,49] paliperidone ER and
risperidone were identified as dominant therapies, olan-
zapine (€23,621 per QALY) could also be considered to
be a cost-effective option versus haloperidol in the schi-
zophrenia relapse treatment.
Modelling based on a decision tree to project 12-
month consequences of treatment for different antipsy-
chotic therapies has been previously used in other eco-
nomics evaluations [50].
As noted in NICE analysis, the key driver of cost
effectiveness for antipsychotics is their probability to
reduce relapse rates. Indeed, due to lack of head to head
trials between the drugs analyzed, the current analysis is
built on the mixed treatment comparison built on NICE
based on retrospective available data.
The main drivers of the model are probabilities. Data
from a systematic review performed by NICE were used,
due to the lack of head-to-head trials between the drugs
analyzed, although differences in relapse definition over
the 17 studies included in this meta-analysis could lead
to different relapse rates and potentially influence results.
The one-year treatment period was chosen because
most of the clinical trials only assessed efficacy of anti-
psychotics in a 52-week period, and projection of the
efficacy beyond 52 weeks would be a source of bias in
the analysis. On the other hand, the last guideline for
schizophrenia published by NICE considered a lifetime
horizon given the potential need for long-term use of
APS drugs by people with schizophrenia in remission.
The primary limitation of this evaluation was the
omission of other antipsychotics, such as zotepine and
quetiapine. As previously justified, zotepine was not
included because it is not marketed in Spain. Quetiapine
was also excluded due to the lack of relevant clinical
information on this drug related to schizophrenia
relapse prevention.
Table 5 Average cost-effectiveness (CE) and incremental cost-effectiveness (ICE) ratio of assessed antipsychotics versus
haloperidol (€, 2009)





Paliperidone ER 4,043 Dominant
Risperidone 4,353 Dominant




























Figure 3 Incremental cost-effectiveness ratio (ICER) of assessed treatment options versus haloperidol. QALY: Quality-Adjusted Life Year.
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Table 6 Deterministic Sensitivity Analysis (ICERs of assessed antipsychotics versus haloperidol)
Parameter Incremental Cost (€) Incremental QALYs ICER versus haloperidol (€/QALY gained)
Base case (BC)
Amisulpride 925 0.0101 91,584
Aripiprazole 1,390 0.0147 94,558
Olanzapine 574 0.0243 23,621
Paliperidone ER -260 0.0341 Dominant
Risperidone -128 0.0105 Dominant
Probability of relapse +20% BC
Amisulpride 795 0.0099 80,303
Aripiprazole 1,227 0.0144 85,208
Olanzapine 317 0.0258 12,287
Paliperidone ER -632 0.0373 Dominant
Risperidone -279 0.0107 Dominant
Probability of relapse -20% BC
Amisulpride 986 0.0150 65,733
Aripiprazole 1,495 0.0131 114,122
Olanzapine 773 0.0238 32,479
Paliperidone ER 55 0.0326 1,687
Risperidone -35 0.0099 Dominant
Probability of discontinuation due to AE +20% BC
Amisulpride 861 0.0097 88,763
Aripiprazole 1,356 0.0130 104,308
Olanzapine 516 0.0238 21,681
Paliperidone ER -287 0.0319 Dominant
Risperidone -184 0.0099 Dominant
Probability of discontinuation due to AE -20% BC
Amisulpride 930 0.0104 89,423
Aripiprazole 1,373 0.0163 84,233
Olanzapine 575 0.0249 23,092
Paliperidone ER -291 0.0362 Dominant
Risperidone -141 0.0114 Dominant
Probability of discontinuation due to other reasons +20% BC
Amisulpride 868 0.0094 92,340
Aripiprazole 1,358 0.0135 100,593
Olanzapine 490 0.0243 20,165
Paliperidone ER -364 0.0349 Dominant
Risperidone -211 0.0100 Dominant
Probability of discontinuation due to other reasons -20% BC
Amisulpride 923 0.0105 87,905
Aripiprazole 1,363 0.0157 86,815
Olanzapine 601 0.0242 24,835
Paliperidone ER -213 0.0332 Dominant
Risperidone -103 0.0106 Dominant
Dominant: strategy with higher effectiveness (QALYs) and lower cost
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Although antipsychotic medication is associated with a
wide range of adverse events, only EPS, weight gain and
metabolic effects were considered in our evaluation, as
they have been identified to be those with a greater
impact on cost-effectiveness ratio.
Following a conservative approach, tardive dyskinesia
was not included, despite its long-term and important
effects on quality of life, as this event is mainly asso-
ciated with the primary comparator (haloperidol).
Including this side effect could introduce an important
bias in the analysis [18].
The quality-adjusted life year (QALY) is routinely used
as a summary measure of health outcome for economic
evaluation, which incorporates the impact on both the
quantity and quality of life [51] QALYs are obtained by
multiplying life years gained by an utility value. Utilities
represent patient’s preferences by a health state, so they
are strongly related to cultural aspects. Ideal economic
evaluation would be based on data derived from local
population where study is performed [52]. However
publications with Spanish specific utilities values in the
illness of interest are scarce. Although use of values
from other areas could be a potential bias’ source [53],
in the present study, due to the lack of published data
related to Spanish population, utilities from UK where
used for remission, relapse, acute EPS and weight gain.
According the results from the deterministic sensitiv-
ity analysis developed, the model seems to be quite
robust, but probabilistic sensitivity analyses would have
provided additional information to validate this point.
Despite these limitations, the assumptions considered
in the present model appeared to be reasonable and
conservative, and the results of the sensitivity analyses
indicated the robustness of the findings.
The current analysis shows that relapse prevention is
the key driver for cost-effectiveness of antipsychotics in
Spain. This conclusion is fully aligned with the results
of the NICE analysis in the UK, which acknowledges
that drug acquisition costs do not determine the relative
cost-effectiveness of antipsychotic medications. Indeed,
antipsychotic drugs that reduce the rate and duration of
hospital admissions may be cost-saving options in the
long-term, despite higher acquisition costs.
With respect to other Spanish studies, our results are
also aligned with a previous analysis concerning the
costs of schizophrenia in Spain, which showed that
drugs account for only 24% of medical costs of the dis-
ease in Spain, whereas hospitalization accounted for
73% of those costs [54].
A previous investigation in Spain has shown that
number of relapses is directly related to higher treat-
ment costs [20]. The choice of the best alternative to
reduce relapses, in efficacy terms, could indeed impact
in the total schizophrenia cost. According our results
paliperidone ER is the most effective and the least costly
strategy.
Our findings may be of interest to clinicians and
others interested in outcomes and cost of mental health
services among patients with schizophrenia.
Conclusions
In our analysis, paliperidone ER and risperidone were
shown to be dominant antipsychotic therapies compared
to haloperidol in Spain. However, as pointed out by
NICE, it is worthwhile to highlight that schizophrenia is
a highly incapacitating disease and choosing the most
appropriate drug and formulation for a particular
patient is crucial. The prevention of relapses is a key
factor in the efficiency of the antipsychotics.
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